Doximity Stock Explodes 37% as Doctors and Wall Street Bet Big on Its Game-Changing Growth [Yahoo! Finance]
Doximity, Inc. Class A (DOCS)
Company Research
Source: Yahoo! Finance
Revenue hit $136.8 millionup 20% year-over-yearblowing past the $127.1 million analysts had penciled in. Adjusted earnings of $0.30 per share also crushed forecasts of $0.26. But the real mic-drop moment? Over 600,000 doctors are now actively prescribing through Doximity's platform, setting a record and underscoring the company's game-changing role in healthcare. CEO Jeff Tangney nailed it: Doximity isn't just saving doctors time; it's rewriting the rules for how patient care gets delivered. Wall Street's taking noteand fast. KeyBanc gave the stock a big thumbs-up, upgrading it to "Overweight" with a new $70 price target, citing "very healthy" earnings and long-term momentum. Wells Fargo joined the fan club, boosting its price target to $41 from $19. Both upgrades followed Doximity's revised full-year guidance, now forecasting revenue between $535 million and $540 million, with adjusted EBITDA expected to soar up to $279 million. The message? Doximity's growth story is just getting
Show less
Read more
Impact Snapshot
Event Time:
DOCS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DOCS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DOCS alerts
High impacting Doximity, Inc. Class A news events
Weekly update
A roundup of the hottest topics
DOCS
News
- Doximity, Inc. (NASDAQ: DOCS) had its price target raised by analysts at JPMorgan Chase & Co. from $30.00 to $48.00. They now have a "neutral" rating on the stock.MarketBeat
- Zacks.com featured highlights Doximity, Impinj and Innodata [Yahoo! Finance]Yahoo! Finance
- TikTok ‘dermfluencers' have medical students flocking to dermatology, where they can make half a million dollars a year and work four days a week [Yahoo! Finance]Yahoo! Finance
- TikTok ‘dermfluencers' have medical students flocking to dermatology, where they can make half a million dollars a year and work four days a week [Fortune]Fortune
- Polen U.S. Small Company Growth Strategy Exited Doximity (DOCS) Due to Multiple Factors [Yahoo! Finance]Yahoo! Finance
DOCS
Earnings
- 11/7/24 - Beat
DOCS
Sec Filings
- 11/15/24 - Form 4
- 11/15/24 - Form 4
- 11/14/24 - Form SC
- DOCS's page on the SEC website